Medical Economics November 8, 2024
Mike Hollan

Key Takeaways

  • Trump’s administration may attempt to repeal the Affordable Care Act and the Inflation Reduction Act, affecting drug pricing.
  • Robert F. Kennedy Jr.’s potential role in health policy introduces uncertainty, especially regarding vaccine skepticism.
  • Industry leaders stress the importance of the FDA’s science-based, patient safety-focused standards.
  • The US healthcare system struggles with high costs and modest health outcomes compared to other countries.

A panel at the Financial Times’ 2024 Global Pharma and Biotech Summit in London analyzed what the re-election of Trump could mean to the pharmaceutical industry.

Donald Trump’s victory in the 2024 US presidential election is sure to have an impact on the pharmaceutical industry. During a panel at the Financial Times’ 2024 Global Pharma...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Conferences / Podcast, Congress / White House, Govt Agencies, Pharma, Pharma / Biotech, Trends
Related Articles:
What Might the Future of Prescription Drugs Look Like Under Trump?
An Open Letter to the Next Administration Regarding Primary Care
Trump promised a role to RFK Jr. What could that mean for healthcare?
The Trump Sequel: What to Expect on PBMs, 340B, Drug Pricing, and RFK Jr
Health Dose: Post-Election Edition

Share This Article